Tests Used in Cancer Diagnosis and Treatment: Molecular and Genetic Analyses

🚀 Why Does It Matter?

The paradigm in cancer care has shifted from morphology-based classification to an approach centered on the tumor's biological/genomic identity within personalized medicine . This transformation improves diagnostic accuracy, helps us predict recurrence risk earlier, and increases the chance of giving the right treatment to the right patient .

• Prognostic data: predict disease course and recurrence risk → influence follow-up and adjuvant treatment decisions.
• Predictive data: predict the benefit/toxicity expected from a particular treatment → shape treatment selection and dosing.
• Integrated approach: IHC + PCR + NGS + MRD + pharmacogenomics + microbiome → comprehensive decision support.

Introduction: The Evolution of Diagnosis and Prognosis in Personalized Oncology

Modern oncology has evolved from individual markers to multilayer profiling. Multiple "data channels" are now interpreted together, including not just a tumor's microscopic appearance but protein expression (IHC), target mutations (PCR), genome-wide variants (NGS), residual disease (MRD), drug metabolism (pharmacogenomics) and the microbiome . The aim: more accurate prognosis and greater treatment benefit with less toxicity.

📌 Quick Summary

• Prognostic = The natural course of disease (recurrence, survival).
• Predictive = Response/toxicity with a specific treatment.
• Clinical value = Follow-up strategy + treatment selection + dose adjustment + adverse effect management.

📊 Prognostic and Predictive Factors: Side by Side

🧠 Remember

• Prognostic ≠ Predictive; they are often interpreted together.
• For decision support, data become meaningful through multiple tests and multidisciplinary assessment.
• The goal: less unnecessary treatment, greater benefit, safer care.

🔬 Immunohistochemistry (IHC): From Tissue Pathology to Molecular Information

Immunohistochemistry (IHC) is a fundamental method that enables the detection of specific proteins or antigens in tissue sections using antibodies . It shows not genetic material, but directly protein expression . This makes it essential for both diagnosis and treatment planning.

📌 Clinical Applications

• Diagnosis and Differential Diagnosis: distinguishing adenocarcinoma ↔ squamous cell carcinoma in NSCLC (TTF-1, p40/p63).
• Tumor Origin: in metastatic cases with an unknown primary (breast, colon, lung markers).
• Staging & Prognosis: assessing the extent of spread and disease course.

🌟 Important Biomarkers and Their Clinical Meaning

Breast cancer is the field where IHC biomarkers are used most extensively:

• ER/PR: positive in approximately 70% of cases → for tamoxifen and other hormone therapies, predictive.
• HER2: overexpression in 10–20% of cases → both a marker of poor prognosis and, for sensitivity to treatments such as trastuzumab, predictive.

⚠️ Clinical Note

HER2 assessment is reported as 0, 1+, 2+, 3+ scores. 0 and 1+ → HER2-negative, 3+ → positive are the interpretations. 2+ = equivocal → confirmation always requires a FISH test .

This shows that no test alone can make an "absolute decision" in modern oncology and that integration of multiple data sources is essential.

🧠 Remember

• IHC → protein-level biomarker analysis.
• For guiding breast cancer treatment, ER/PR and HER2 are the gold standard.
• Additional testing (FISH) should be performed in equivocal cases.

🧪 Polymerase Chain Reaction (PCR): Targeted Gene Amplification

PCR is a rapid, highly sensitive technique that enzymatically amplifies specific DNA regions to make them detectable. In oncology, it plays a critical role in detecting viral agents, mutation/fusion analysis and minimal residual disease (MRD) monitoring .

📌 Main Clinical Uses

• HPV Detection: 70% of cervical cancers are caused by high-risk HPV (16 & 18). PCR-based HPV testing detects the virus before cancer develops.
• Mutations & Fusions: confirming target mutations such as EGFR mutations or EML4–ALK fusions.
• MRD Monitoring: in hematological cancers such as leukemia, detecting post-treatment residual disease markers such as the Philadelphia chromosome .

⚠️ Clinical Note

Although PCR is powerful, it may have approximately a 30% margin of error . Results must therefore be assessed together with clinical findings and imaging .

🧠 Strengths and Weaknesses

• Advantage: fast, inexpensive, highly sensitive.
• Disadvantage: the margin of error may be high; only a limited number of genes/regions can be tested.
• Clinical Value: in early diagnosis, recurrence monitoring, and confirmation of target mutations, it plays a complementary role .

🧬 Next-Generation Sequencing (NGS): Mapping Genomic Profiles

By reading millions of DNA/RNA fragments in parallel, NGS generates a comprehensive tumor profile . It goes beyond single-gene testing to provide extensive information on mutations, copy number variations (CNVs), microdeletions/insertions, fusions and biomarkers (TMB, MSI) in a single analysis .

📊 Somatic vs. Germline NGS: Purpose and Clinical Yield

🧠 Panel Design: What Should We Look At?

• Panel breadth: clinical panels generally cover 50–500+ genes ; they may be indication-specific (lung, GI, etc.) or tumor-agnostic.
• Coverage depth: determines the detection threshold (limit of detection); high depth is needed to detect low VAFs in ctDNA.
• Capture strategy: hybrid capture (broad coverage) vs amplicon (target-focused, fast); for fusions, adding RNA-seq increases sensitivity.
• Reporting standard: specifying the actionability tier (level 1–4) using AMP/ASCO/CAP classification facilitates clinical decisions.

🛡️ Immunotherapy Biomarkers: TMB & MSI

• TMB (Tumor Mutational Burden): a high mutation count may enhance the immune response in some tumors → helps identify ICI candidates.
• MSI (Microsatellite Instability): MSI-H/dMMR tumors may be sensitive to ICIs; this may also indicate hereditary Lynch syndrome.

💧 Liquid Biopsy (ctDNA): When Is It Preferred?

• If tissue is insufficient/unavailable or when seeking to identify a resistance mechanism during treatment.
• Sensitivity depends on tumor burden: a ctDNA-negative result may not mean definitive exclusion → complementary tissue testing is recommended.
• Rapid turnaround and repeatabilityoffer advantages for serial monitoring (e.g., an MRD-like approach).

⚠️ Limitations (and How to Manage Them)

• VUS (Variant of Uncertain Significance): complicates clinical interpretation → discuss in a multidisciplinary molecular tumor board meeting.
• TAT (turnaround time): usually 2–3 weeks → if urgent treatment is needed, bridge with targeted PCR/IHC testing.
• Differences in scope: panel contents vary → make sure indication-specific targets are listed (e.g., RNA for fusions).
• Preanalytical variables: FFPE fixation time, tumor cell percentage; preferring tumor cellularity > 20% improves result quality.

🧷 Remember

• NGS = multiple biomarkers on a single platform → targeted treatment, ICI selection, clinical trial matching.
• Somatic + Germline should be considered together; inherited findings require genetic counseling .
• ctDNA does not replace tissue; it is complementary; a negative result may not rule disease out.

🔍 Minimal Residual Disease (MRD): An Early Warning of Recurrence

Minimal Residual Disease (MRD)means tumor cells remaining at a microscopic levelafter treatment that conventional imaging cannot detect. Its presence is one of the most important determinants of recurrence. It has entered routine practice particularly in hematological cancers, while in solid tumors it has become a rapidly growing field using ctDNA-based tests .

📌 MRD Detection Methods

• Liquid biopsy (ctDNA): can detect recurrence in solid tumors 9–10 months before imaging.
• Flow cytometry: in hematological cancers such as leukemia/lymphoma, detects cells that cannot be identified morphologically .
• NGS-based MRD: detects residual mutations with high sensitivity and enables personalized follow-up.

⏳ MRD and Recurrence Timeline

• 📅 Month 0: after surgery/chemotherapy, the patient appears to have a "complete response."
• 🧬 Month +3: ctDNA begins to detect signs of microscopic residual disease .
• 🖥️ Months +9–10: imaging detects recurrence.

👉 MRD detection with ctDNA may provide an early warning approximately 1 year before conventional methods .

🧠 Clinical Importance

• Hematological cancers: guides transplant/treatment decisions in ALL and AML.
• Solid tumors: ctDNA-negative patients with colorectal cancer may show similar survival even without chemotherapy.
• Personalized follow-up: MRD-positive → early intervention; MRD-negative → avoiding overtreatment.

📈 Recurrence Scoring Tests: Oncotype DX and Clinical Guidance

Recurrence scoring tests play a critical role in determining the need for chemotherapy, particularly in patients with early-stage hormone receptor-positive, HER2-negative breast cancer . The pioneering test, Oncotype DX, analyzes the expression of 21 genes to calculate a recurrence score (ranging from 0–100).

🔬 How Does the Test Work?

• RNA is isolated from tumor tissue.
• 16 tumor-related genes + 5 reference genes have their expression levels measured.
• The algorithm calculates a 0–100 Recurrence Scorefrom these data.

🧠 Clinical Meaning of Scores

• Low Score (0–25): low recurrence risk. According to TAILORx data, 70% of this group gained no benefit from chemotherapy. → Unnecessary chemotherapy is avoided.
• High Score (≥26): high recurrence risk, greater likelihood of metastasis. → Chemotherapy provides substantial benefit for these patients.

⚠️ Clinical Note

Oncotype DX can be used not only in invasive cancers, but also in DCIS (Ductal Carcinoma in Situ) cases. Here, the aim is to determine local recurrence risk and guide radiotherapy decisions .

📌 Remember

• Oncotype DX = One of the strongest genomic tests for preventing unnecessary chemotherapy.
• Major studies such as TAILORx → strengthened the personalized treatment paradigm.
• Beyond conventional factors (tumor size, stage), the recurrence score sheds light on biological behavior .

🧪 Pharmacogenomic Tests: Predicting Drug Response and Toxicity

Pharmacogenomics personalizes treatment by identifying the patient's genetic variants affecting drug metabolism . In oncology, its aim is to reduce toxicity while maintaining efficacyand, if needed, adjust the starting dose and consider alternative regimens.

📌 Why Does It Matter?

• It can predict high-risk toxicity (neutropenia, mucositis, delayed diarrhea).
• Dose reduction/alternative treatment can reduce emergency visits and treatment interruptions.
• It is performed using a routine blood test; results are reusable (lifelong information).

🧬 Examples: The Most Common Gene–Drug Pairings

⚠️ Clinical Note

• DPYD: with intermediate/reduced DPD activity, the starting 5-FU/capecitabine dose is reduced and gradually increased according to toxicity.
• UGT1A1: for irinotecan in *28/*28 cases, labels and guidelines recommend a reduced starting dose and close monitoring.
• Ethnic differences (allele frequencies) may affect clinical interpretation; always review the phenotype (activity score) in the report.
• Pharmacogenomics does not determine the decision alone ; it is assessed together with kidney/liver function, concomitant drugs, and clinical condition .

🧭 A Practical Approach

1. Test beforehand: according to the planned regimen (e.g., FOLFOX/XELOX → DPYD; FOLFIRI → UGT1A1).
2. Start according to phenotype: reduce the dose by 20–50% according to activity/risk, or use an alternative regimen.
3. Monitor closely: monitor blood counts and diarrhea/mucositis during the first 2 cycles; if needed, use titration.
4. Document & share: retain results in the record as a permanent alert similar to a "drug allergy."

🦠 The Microbiome and Cancer Treatment: A New Research Frontier

The human gut microbiota plays a critical role not just in digestion, but also in immune system regulation and disease development . Imbalance (dysbiosis) has been linked to many tumors, especially colorectal cancer . In recent years, the microbiome has been shown to directly affect the efficacy and toxicity profile of cancer treatment.

🛡️ Immunotherapy Response and the Microbiome

• Akkermansia muciniphila and certain other bacteria may improve immunotherapy response.
• Low Akkermansia levels → were associated with resistance .
• In mouse models, microbiome modification through fecal transplantation restored immunotherapy efficacy.

💊 Chemotherapy and Toxicity

• Healthy microbiota → reduces the risk of chemotherapy-related diarrhea and mucositis .
• Antibiotic use may reduce immunotherapy efficacy by disrupting microbiome balance.
• Unlike genetic factors, the microbiome is a modifiable biomarker.

⚠️ Clinical Note

In the future, treatment protocols are expected to be personalized not just genetically, but also according to the microbiome profile . This could both improve efficacy and reduce toxicity.

📌 Remember

• Microbiome = a key regulator of immunotherapy response.
• Dysbiosis → associated with cancer development and treatment failure.
• Modifiable → probiotics, diet, fecal transplantation are potential strategies.

🧫 Organoid Tests: A Bridge from Laboratory to Patient

Patient-derived organoidsare three-dimensional cell culture systems that preserve a tumor's genetic and biological characteristics in the laboratory. This technology enables drug sensitivity tests to predict actual patient responses with high accuracy.

🏥 Clinical Applications

• Drug selection: in pancreatic, colon, and rectal cancers, organoid drug response ≈ the patient's actual response.
• Targeted treatment guidance: organoids with ARID1A mutations → high sensitivity to ATR inhibitors.
• Immunotherapy: organoid–immune cell coculture → patient T cells can recognize and destroy their own tumor.

🚀 Advantages

• Patient-specific, real-time drug testing is possible.
• High-throughput screening: 1000+ drugs can be tested at once → discovery of new uses.
• Compared with animal models, cheaper, faster, and more human-specific.

⚠️ Clinical Note

Organoid tests are not yet widespread in routine practice, but many clinical trials are ongoing. In the near future, they are expected to become the most important tool for patient-specific treatment decisions .

🤖 New-Generation Approaches Integrating AI

Alongside organoid tests, AI-supported algorithmic platforms are also developing. The ENLIGHT algorithm and similar systems aim to predict the most suitable treatment for a patient by analyzing genomic data with machine learning.

⚙️ Main Features

• Data Integration: considers not only known mutations but also interactions between genes and whole-genome/exome data.
• Machine Learning: uses models trained on genetic + clinical data from thousands of patients.
• Treatment Response Prediction: generates a probability or score for the efficacy of specific treatments.

🔎 Reliability and Validation

• Retrospective success → many algorithms perform well in retrospective analyses.
• The missing link: large-scale prospective clinical studies remain limited.
• Regulation: most algorithms currently have "research use only" status.

🌐 Other Algorithmic Approaches

• OncoCast-MPM: a model combining clinical + genomic data to predict risk groups (MSKCC).
• Adaptive radiotherapy planning: AI-supported devices revise treatment plans according to daily changes in tumor anatomy.
• Pathology and imaging support systems: reduce errors in tumor detection and reporting.

⚠️ Clinical Note

Although promising, these algorithms have limited use in routine clinical practice without independent prospective validation and regulatory approval . For now, they should be seen as complementary tools supporting doctors' decisions.

🌟 Conclusion and Future Perspectives

Diagnostic and treatment approaches in oncology are now determined not only by tumor size or stage, but by its genetic, biological, and functional signatures . This journey, from conventional methods such as IHC and PCR to NGS and ctDNA-based MRD testsand then to organoid models and AI algorithms , is moving modern oncology toward the vision of precision and personalized medicine .

🔗 An Integrated Approach: The Oncology of the Future

• Conventional tests → Clarify the tumor's biological identity (IHC, PCR).
• NGS & ctDNA → Genome-wide profile + prediction of early recurrence.
• Organoids → Patient-specific drug sensitivity tests.
• Algorithms & AI → Quantitative prediction of treatment response through data integration.

🚀 A Vision of the Future

In the near future, this triad will be central to patient management:

1. Genetic signature: mutational burden, MSI, drug metabolism genes.
2. Functional tests: organoid- and cell-based drug sensitivity studies.
3. AI-supported decision systems: individualized treatment selection using algorithms that learn from thousands of data points.

This transformation requires multidisciplinary teamwork : oncologists, geneticists, bioinformatics specialists, and AI engineers are working together to build the oncology of the future.

📌 Remember

• Oncology is now focused on more than a single biomarker; it is a multilayered science.
• Early recurrence detection (MRD, ctDNA) is key to improving treatment success.
• Organoids and algorithmswill shape the future of personalized treatment.